Ultragenyx Pharmaceutical Inc.
Company Stats
- Market Cap
- $1.5B
- as of Sep 30, 2026
- Shares Outstanding
- 98.6M
- Free Float
- 93.1%
Income Statement
- Revenue
- $673.0M
- Operating Income
- -$535.0M
- Net Income
- -$575.0M
- EBITDA
- -$500.0M
- Revenue Growth, 3Y
- 22.8%
- FCF Margin, 3Y Avg
- -88.3%
- FCF Margin, Worst Year
- -119.6%
Cash Flow
- Free Cash Flow
- -$472.0M
- FCF Yield
- -31.9%
- Owner FCF Yield
- -42.2%
Balance Sheet
- Cash & Equivalents
- $421.0M
Returns & Capital
- SBC, 3Y Avg
- $148.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $673.0M | -$472.0M | -70.1% |
| FY2024 | $560.0M | -$421.0M | -75.2% |
| FY2023 | $434.0M | -$519.0M | -119.6% |
| FY2022 | $363.3M | -$496.6M | -136.7% |
| FY2021 | $351.4M | -$411.8M | -117.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 15, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back